BREAKING NEWS
This content is not available in your region

Roche's Alecensa latest beneficiary of faster China drug approvals

Roche's Alecensa latest beneficiary of faster China drug approvals
FILE PHOTO: Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration/File Photo   -   Copyright  Dado Ruvic(Reuters)
Text size Aa Aa

ZURICH (Reuters) – Chinese regulators are speeding up drug approvals, with Roche’s <ROG.S> Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans.

China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.

(Reporting by John Miller)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.